Despite the lack of internationally shared treatment guidelines, the current approach supports the use of IL-1 inhibitors in patients with Still’s disease (14, 16), while IL-6 antagonists may represent an effective treatment choice in refractory cases with persistent inflammatory joint involvement (15, 17). This evidence concerns the gene IL1B and systemic-onset juvenile idiopathic arthritis.